Close Navigation
AboutStrategyTeamPortfolioInsightsMediaContact
Investors
Overlay

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

12th June 2020

Useful Tools

Download, print or share this article

Print Print Article Email Email Article
Print Save Article
Share Article
TwitterTwitterLinkedInLinkedInFacebookFacebook